Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$76.54 USD
-0.81 (-1.05%)
Updated May 17, 2024 04:00 PM ET
After-Market: $76.57 +0.03 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AXSM 76.54 -0.81(-1.05%)
Will AXSM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXSM
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Other News for AXSM
The 3 Most Undervalued Biotech Stocks to Buy in May 2024
Why Axsome Therapeutics Is A Promising Stock Pick In CNS Treatments
Axsome Therapeutics to Present at Upcoming Investor Conferences
Axsome Therapeutics price target lowered by $3 at Mizuho, here's why
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Teleflex (TFX) and Axsome Therapeutics (AXSM)